CAP Molecular Diagnosis of Lung Cancer
Jump to navigation
Jump to search
Expand List 5 treatment defining molecular transformation, the neoplasm, and the genetic alteration
|
---|
Expand List and describe 5 areas of Genetic characaterization of tumours for personalized medicine
|
---|
Expand What fraction of Lung adenocarcinomas have no known detactable mutations
|
---|
Expand What are the three most common molecular alterations of Lung Adenocarcinoma
|
---|
Expand What is the two most common molecular alteration makes patients with EGFR mutations resistant to targetted therapies?
|
---|
Expand List two EGFR kinase inhibitors.
|
---|
Expand What are the three most common cancers associated with KRAS mutations?
|
---|
Expand Why don't KRAS + tumours respond to Anti EGFR therapies?
|
---|
Expand Explain the cost effectiveness of genetic testing for targetted therapies?
|
---|
Expand What are the three most common cancers associated with BRAF mutations?
|
---|
Expand Beta catenin/CTNNB1 expression is found with which histological pattern of lung adenocarcinoma?
|
---|
Expand What is the most common ALK rearrangement found in NSCLC?
|
---|
Expand List some pros and cons of ALK FISH.
|
---|
Expand List some pros and cons of ALK IHC.
|
---|
Expand What is a positive count in the ALK-FISH?
|
---|